Federal Project Grant Award Summary

The National Heart, Lung, and Blood Institute (NHLBI) awarded The Broad Institute, Inc. a Project Grant totaling $173,825 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period July 1, 2026 through June 30, 2031. The award funds functional genomics research to investigate gene regulatory networks in cardiac fibrosis, addressing a critical gap in understanding the transcriptional mechanisms that drive and maintain activated cardiac fibroblast cell states in heart failure patients. The project applies large-scale genomic screening methodologies to characterize gene regulatory networks in cardiac fibroblasts, with the objective of identifying transcriptional regulators responsible for promoting the activated fibroblast phenotype that contributes to excessive extracellular matrix deposition and ventricular wall stiffening in heart failure.

As a specialized genomics and precision medicine research infrastructure provider, The Broad Institute delivers advanced functional genomics analysis, large-scale transcriptomic profiling, and computational biology support to enable mechanistic understanding of cardiac fibrosis pathology. This research directly supports the NHLBI's mission to advance basic and translational science on cardiovascular diseases and contributes to the broader research portfolio addressing the substantial public health burden of heart failure affecting over 6 million U.S. adults. The award represents foundational research intended to facilitate development of antifibrotic therapies, for which no effective treatments currently exist.